EMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged Children

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") contributed to the development of a pediatric formulation to treat schistosomiasis as a member of the Pediatric Praziquantel Consortium (Consortium). The Consortium announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive scientific opinion for arpraziquantel to treat one of the neglected tropical diseases, schistosomiasis, in preschool-aged chi

Related Keywords

Switzerland ,Japan ,Uganda ,Netherlands ,Makerere ,Kampala ,Kenya ,United Kingdom ,Germany ,Swiss ,Naoki Okamura ,Technischen Universit ,Public Health Institute Switzerland ,Ministry Of Health Kenya ,Ntds Control Division Uganda ,Kenya Medical Research Institute ,Division Of Vector Borne ,Access To Health ,Ministry Of Health ,Unlimit Health United Kingdom ,Development Kenya ,Consortium Partners ,Ministry Of Health Uganda ,Pediatric Praziquantel Consortium ,Makerere University School Of Public Health Uganda ,Praziquantel Consortium ,Astellas Pharma Inc ,African Institute For Health ,World Health Organization ,Pediatric Praziquantel ,Swiss Tropical ,Public Health Institute ,Medical Research Institute ,University School ,Public Health ,Health Kenya ,Vector Borne ,Health Uganda ,Control Division ,Focus Area Approach ,Astellas Pharma ,Neglected Tropical Diseases ,Consortium ,Schistosomiasis ,European Medicines Agency ,Aediatric Formulation ,African Countries ,Endemic Countries ,Praziquantel ,